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Peritoneal Transport: From Basics to Bedside
Tao Wang, Bengt Lindholm1
Comprehensive understanding of peritoneal solute and fluid transport is of clinical significance to nephrologists
in guiding prescription of peritoneal dialysis. In this review, we discuss the basic knowledge of peritoneal
transport and its relationship with the prescription of peritoneal dialysis and new peritoneal dialysis solutions.
The roles of neoangiogenesis, peritoneal inflammation and changes in peritoneal hydraulic permeability,
especially changes in tissue hyaluronan content and peritoneal surface layer, are also discussed. [Hong Kong J
Nephrol 2003;5(2):65–72]
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INTRODUCTION
Peri toneal  dialysis  therapy is  based on the
understanding of how solutes and fluids are transferred
across the peritoneal membrane [1–3]. Therefore, a
comprehensive understanding of peritoneal solute and
fluid transport is of clinical significance to nephrologists
in guiding prescription of peritoneal dialysis. In this
review, we discuss the basis for peritoneal transport
and its relationship with peritoneal dialysis prescription
and new peritoneal dialysis solutions.
PERITONEAL TRANSPORT PHYSIOLOGY
The kinetics of solute and fluid removal from the
peritoneal cavity during peritoneal dialysis have been
studied extensively, yet the precise transport pathways
remain incompletely understood [4,5]. Although
various mathematical models have been used to
describe peritoneal transport [6–8], the simple approach
shown in Figure 1 deals with the net transferred solutes
and fluid, which are clinically relevant regardless of
the complexity of the peritoneal membrane [9].
Solute transport
Removal of uremic toxins (solutes) from the patient
occurs across the peritoneal membrane by two major
mechanisms: diffusion and convection [10,11].
As shown in Equation 1, the rate of solute transport
by diffusion is proportional to the solute concentration
difference between blood (or, more precisely, plasma
water) and the dialysis fluid within the peritoneal cavity,
the membrane diffusive transport coefficient (KBD),
which is a lumped parameter determined by surface
area, and solute permeability, which is inversely
proportional to the molecular weight of the solutes [9,
12,13]. It follows that, for any specific peritoneal
membrane transport characteristic, the higher the
molecular weight of the solute, the lower the KBD. It
is thus not difficult to understand that the removal of
small solutes in peritoneal dialysis is dialysate-flow-
dependent since their equilibration rate is quick
compared to the removal of large solutes, which is
dialysis-time-dependent (Figure 2).
Convective transport during peritoneal dialysis
refers to solute removal as a direct result of fluid
movement into and out of the peritoneal cavity [14].
The rate of convective solute transport that occurs from
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the blood into the dialysis solution is proportional to
the transcapillary ultrafiltration rate and sieving
coefficient of the peritoneal membrane. A sieving
coefficient of 1 indicates no rejection of the solute by
the peritoneal membrane, whereas a lower value
indicates hindrance to solute transport relative to fluid
movement [15]. Convective solute transport from the
dialysis solution into the peritoneal tissues and blood
occurs during peritoneal fluid absorption [16]. The
mechanism of this process is not yet completely
understood. Fluid transport by this pathway is directed
out of the peritoneal cavity and includes both direct
absorption into peritoneal tissues and transport into
lymphatic vessels [17]. Therefore, the overall rate of
peritoneal solute transport by convection is the
difference between the two separate pathways, as shown
in Equation 1 [6].
Fluid transport
Peritoneal transcapillary ultrafiltration and peritoneal
fluid absorption occur simultaneously during peritoneal
dialysis [18–20]. Net fluid removal depends on the
balance between these two processes [14], as shown in
Equation 2 [21]. During peritoneal dialysis, significant
peritoneal transcapillary ultrafiltration can be achieved
only when osmotic agents are added to the dialysis
solution, creating an osmotic gradient between the
dialysate and blood. Peritoneal fluid absorption is
mainly driven by the intraperitoneal hydrostatic
pressure (IPP) [20], which is strongly dependent on the
intraperitoneal dialysate volume.
Figure 1. Simple model describing peritoneal fluid and solute transport.
Fluid and solute are transferred from the blood to dialysate
simultaneously with the opposite transfer process.
Equation 1
Qs = KBD = (CB – CD) + Qu = S = Cm – Qa = CDav
Qs = net transferred mass; KBD = diffusive mass
transport coefficient; CB = solute concentration in
blood; CD = solute concentration in dialysate;
Qu = transcapillary ultrafiltration rate; S = sieving
coefficient; Cm = mean tissue concentration of the
solute; Qa = peritoneal fluid absorption rate (which
can be estimated using the elimination rate of
intraperitoneal high molecular weight substances
such as albumin); CDav = mean dialysate con-
centration of the solute.
Blood          Membrane        Dialysate
Figure 2. Solute transport across the peritoneal membrane as
assessed by dialysate-to-plasma solute concentration ratio
(D/P ratio).
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Equation 2
QV = LpA = [(PB – PD) – Ymi = RT(CiB – CiD)] – Qa
QV = change in intraperitoneal volume (the net
result of peritoneal transcapillary ultrafiltration and
peritoneal fluid absorption); LpA = total hydraulic
permeability of the membrane; PB – PD =
hydrostatic pressure gradient between the blood and
dialysate; mi = Staverman reflection coefficient; RT
(CiB – CiD) = osmotic pressure gradient; Qa = fluid
absorption rate (to tissues and lymphatics).
Due to the decrease in osmotic gradient with the
prolongation of the dwell time and peritoneal fluid
absorption, the intraperitoneal volume will decrease
after an initial increase (Figure 3). Fluid absorption
significantly decreases peritoneal dialysis efficiency
[22–24]. Mactier et al found that peritoneal fluid
absorption reduced the potential net ultrafiltration by
83.2 ( 10.2% [25]. The contribution of peritoneal fluid
absorption to low dialysis efficiency as regards the net
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removal of fluid is more significant in high transporters
and when 1.36% glucose solution is used [23]. Solute
clearance may also decrease accordingly, especially
when the membrane transport rate is high, such as in
high transporters. Mactier et al found that fluid
absorption decreased urea clearance by 16.9 ( 1.9%
and creatinine clearance by 16.5 ( 1.9% in one 6-hour
exchange [25]. This suggests that prolonging the dwell
time may not only worsen the fluid balance but also
decrease the efficiency of small solute removal,
although clearances for large molecular substances
increase with dwell time [23]. Reduction in peritoneal
fluid absorption may therefore provide an alternative
means of augmenting the efficiency of long-dwell
peritoneal dialysis.
PERITONEAL MEMBRANE AND PERITONEAL
TRANSPORT
The importance of peritoneal transport has been
increasingly recognized. There is a high variation in
peritoneal transport rate among individual patients [3].
This will not only affect the choice of optimal dialysis
prescription, but also patient outcome. Recent studies
suggest that a patient’s peritoneal transport pattern has
a significant impact on clinical outcome, including
patient and technique survival [26–28]. In these studies,
an increased peritoneal transport rate was associated
with lower patient survival. A high peritoneal transport
rate is associated with increased peritoneal small solute
transport and therefore increased peritoneal glucose
absorption, resulting in a faster decrease in osmotic
gradient. A high transport rate is also associated with
increased peritoneal fluid absorption. These two
processes significantly decrease peritoneal fluid
removal and increase the risk of fluid overload [28].
Because of the negative impact of a high peritoneal
solute transport rate on fluid removal, a high peritoneal
solute transport rate is associated with a decreased
removal of rapidly equilibrating solutes such as urea,
and especially of sodium [28]. The net removal of these
solutes is mainly dependent on net fluid removal. Thus,
patients with a high peritoneal solute transport rate are,
in fact, characterized by a low net removal of small
solutes.
Unfortunately, it is not uncommon for peritoneal
membrane permeability to increase with time on
peritoneal dialysis, resulting in decreased peritoneal
ultrafiltration in long-term peritoneal dialysis patients
[29,30]. Although glucose has been blamed for the
changes in the function of the peritoneum, the exact
mechanism of increased peritoneal solute transport rate
is unclear. Understanding the pathophysiology of
increased peritoneal transport rate may thus be very
important for the success of long-term peritoneal
dialysis treatment.
Neoangiogenesis and increased peritoneal
transport rate
An increased peritoneal solute transport rate may be
due to increased peritoneal vascular surface area, either
functionally (e.g. by opening previously closed
capillaries) or anatomically (by increasing the number
of new capillaries) [5]. This theory has been supported
by two observations: that long-term peritoneal dialysis
may result in an increase in the thickness of the
peritoneal membrane and neoangiogenesis in the
peri toneal  membrane [31–33];  and that  the
concentration of vascular endothelial growth factor
(VEGF), the most important growth factor involved in
neoangiogenesis, in the dialysate was correlated with
peritoneal membrane permeability and inversely
correlated with peritoneal ultrafiltration rate [34]. A
high glucose concentration in the dialysate can increase
VEGF production, and the suppression of VEGF
production may prevent functional changes in the
peritoneal membrane [35–37]. Furthermore, increasing
the peritoneal surface area by introducing vasodilatation
agents such as nitroprusside into the dialysis solution
could increase the peritoneal solute transport rate and
clearance [38,39]. Although nitroprusside-induced
vasodilatation increases the peritoneal small solute
transport rate, it does not result in the typical peritoneal
fluid transport kinetics of high peritoneal transporters
[40], i.e. increased peritoneal fluid absorption rate and
decreased peritoneal fluid removal [28]. Therefore,
neoangiogenesis may not necessarily play a central role
in increased peritoneal membrane permeability.
Chronic inflammation and peritoneal transport
rate
Peritoneal inflammation can increase the peritoneal
solute transport rate [11], and chronic peritoneal
Figure 3. Changes in intraperitoneal volume with dwell time for
different glucose peritoneal dialysis solutions.
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dialysis may itself induce (by incompatible peritoneal
dialysis solutions) chronic inflammation of the
peritoneal membrane [41]. Therefore, a high peritoneal
solute transport rate might be caused by a state of
chronic inflammation which also might result in
increased mortality. However, we did not find that the
peritoneal transport rate was associated with increased
dialysate and serum cytokine levels and hyaluronan
levels, suggesting that a high peritoneal transport rate
is not necessarily related to a state of chronic
inflammation in patients on continuous ambulatory
peritoneal dialysis [42].
Peritoneal surface layer and peritoneal transport
rate
Peritoneal tissue hydraulic conductivity plays an
important role in peritoneal fluid (both from blood to
peritoneal cavity and vice versa) and solute transport
[16]. Growing evidence suggests that the hyaluronan
content in the interstitium may be the major determinant
of the fluid exchange barrier in tissues [43]. Hyaluronan
is a long chain polysaccharide that is made up of
repeating disaccharide units of N-acetylglucosamine
and glucuronic acid. It is found in most tissues in the
body [44] and in the drainage dialysis fluid during
peritoneal dialysis [45]. Hyaluronan exhibits a high
resistance against water flow [43,46,47]. In the
interstitium, hyaluronan decreases the water
permeability of the membrane [48,49].
Hyaluronan is a water-soluble substance.
Hyaluronan in the tissue may be easily extracted even
by buffer solution [48]. Furthermore, hyaluronan may
be washed out from the muscle of the anterior
abdominal wall to its adjacent subcutaneous space and
may thereby increase interstitial hydraulic conductivity
[50]. Therefore, it is possible that the content of
hyaluronan in the peritoneal membrane, especially that
on the peritoneal surface and in the peritoneal
interstitium, may be reduced during chronic peritoneal
dialysis. We have previously demonstrated that adding
0.01% hyaluronan to the peritoneal dialysis fluid in rats
increases peritoneal fluid removal mainly by decreasing
peritoneal fluid absorption, resulting in increased
peritoneal urea clearance [51]. We also demonstrated
that the decreasing effect of hyaluronan on the
peritoneal fluid absorption rate is even more marked
when a high dialysate fill volume is used [52]. We
speculated that the observed effect of hyaluronan on
peritoneal fluid absorption might be due to the
accumulation of a restrictive filter “cake” of hyaluronan
chains at the tissue-cavity interface, resulting in a high
resistance to fluid flow [51]. This decreasing effect may
depend on both the molecular weight and the
concentration of hyaluronan [53].
To support our hypothesis, we recently demon-
strated that there is, in fact, a peritoneal surface layer
that consists of glycosaminoglycans (including
hyaluronan), as well as surface-active substances
(surfactants) on the peritoneal surface, and that this layer
may play an important role in peritoneal transport,
especially in peritoneal fluid transport [54]. We also
found that repeated intraperitoneal addition of
hyaluronan may prevent the increase in peritoneal
membrane transport rate caused by currently used
hypertonic dialysis solutions, and that this is associated
with a better preservation of the peritoneal surface
layer [55].
Surfactants were first identified in peritoneal
dialysis effluent in 1985 by Grahame and co-workers
[56], and have since raised great interest in peritoneal
dialysis society due to their special physical properties.
Recently, Hills et al demonstrated the presence of a
phospholipid layer (surfactant) on the peritoneal surface
by applying the hydrophobic probe phosphin E [57].
The surfactant consists of a mixture of phospholipids
(67%), proteins (8%), neutral lipids (21%), carbo-
hydrates (2%), and minor constituents (2%) [58]. In
general, besides lowering alveolar surface tension,
surfactants play important roles in local host defense,
tissue permeability and in maintaining fluid balance in
the alveoli [57,59]. However, despite extensive studies
on surfactant physiology, the function of the individual
constituents of surfactants, and especially the role of
the different phospholipids, are, to a large extent,
unknown [60]. In a recent study, we found that the
phosphatidylcholine content significantly decreased
both in the dialysate and in the peritoneal surface layer
when membrane permeability was increased, indicating
that, in addition to lubrication of the peritoneal cavity,
the surfactant, and especially its phosphatidylcholine
content, may play an important role in peritoneal
transport [54]. In fact, several previous studies have
demonstrated that phospholipids,  especially
phosphatidylcholine, decrease peritoneal fluid
absorption rate and increase peritoneal fluid removal
[61–63]. Furthermore, we recently found that damaging
the peritoneal surface layer by intraperitoneal use of
pentobarbital and peritoneal shaking significantly
increased the peritoneal solute transport rate and
peritoneal fluid absorption rate, changes similar to those
observed in high transporters, suggesting the
importance of the peritoneal surface layer in peritoneal
membrane transport (unpublished data).
It has also been suggested that peritoneal membrane
fibrosis may have an impact on increased membrane
permeability [33,64,65]. However, we think that
the association between fibrosis and increased
membrane permeability may not necessarily be
explained by fibrosis per se, but may be due to the
neoangiogenesis and decreased tissue hyaluronan
content that link to tissue fibrosis. The role of water
channels in the changes in membrane permeability
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remains to be determined [66,67].
We therefore believe that an increased peritoneal
membrane solute transport rate may be the consequence
of different complicated pathologic processes. Changes
in the tissue hydraulic conductivity by alteration in the
tissue hyaluronan content and changes in the peritoneal
surface layer may play important roles in this process.
In addition, an increased peritoneal surface area due to
increased angiogenesis and increased permeability of
peritoneal microvessels due to local chronic
inflammation may have synergetic effects on increased
peritoneal solute transport rate.
NEW PERITONEAL DIALYSIS SOLUTIONS AND
THEIR IMPACT ON PERITONEAL TRANSPORT
Peritoneal transport has recently been used as a
parameter to test the biocompatibility of peritoneal
dialysis solutions. It has been suggested that the
bioincompatibility of the currently used glucose-based
peritoneal dialysis solutions may be one of the main
reasons for the changes in membrane permeability [68].
The bioincompatibility factors of the solutions include
low pH, high glucose content, high lactate content, high
osmolality, and high levels of glucose degradation
products that are generated during heat sterilization
[69]. Numerous studies have investigated how the
problems with conventional glucose dialysis solutions
may be overcome [69]. The obvious choice for
replacing the conventional low-pH, high-lactate
buffered peritoneal dialysis solution is a bicarbonate
solution.
Recent clinical trials show that, compared to
conventional lactate-based solutions, bicarbonate/
lactate (B/L) solutions result in an increased CA 125
concentration (a possible indicator of mesothelial cell
mass) and a decreased hyaluronan concentration (an
indicator of inflammation) in dialysate effluent. These
observations suggest that continuous therapy with B/L
solution may reduce the pro-inflammatory potential and
improve mesothelial cell integrity within the dialyzing
peritoneum, possibly indicating better preservation of
peritoneal homeostasis and long-term function of the
peritoneal membrane in patients dialyzed with more
biocompatible solutions [70]. Similar results have been
reported with peritoneal dialysis solutions containing
only a low amount of glucose degradation products
(GDPs),  indicating a possible role of GDPs in altering
the peritoneal membrane during long-term peritoneal
dialysis [71]. It is worthwhile to note that there was a
small but significant increase in peritoneal ultrafiltration
with the B/L solution compared to the conventional
lactate-based solution [70]. These observations support
a previous statement by Oreopoulos and Breborowicz
that “more biocompatible solutions in combination with
more adequate dialysis, would allow peritoneal dialysis
patients to stay on peritoneal dialysis for longer periods
with less fibrosis of the peritoneal membrane, the
maintenance of the peritoneal membrane ultrastructure
and its ability to regenerate, and lower incidence of
ultrafiltration capacity failure” [72].
On the other hand, dialysis solutions with low-
molecular-weight osmotic agents are not ideal for long
dwell-time because the osmotic agent is absorbed,
resulting in a decrease in transcapillary ultrafiltration.
During long dwell-time, high-molecular-weight
osmotic agents are therefore more suitable. Icodextrin
is the only available high-molecular-weight osmotic
agent for peritoneal dialysis solution in clinical practice
so far. It is a polymer of glucose produced by the
hydrolysis of starch. The solution contains a spectrum
of icodextrin molecules with an average molecular
weight of 16,200 d. The polymers consist of glucose
units linked predominantly by _ 1-4 glucosidic bonds,
with a small proportion of branches linked by _ 1-6
glucosidic bonds [73]. Clinical studies show that the
ultrafiltration generated by icodextrin solution for 8 to
12 hours in peritoneal dialysis patients is equivalent
to, or even better than, that of 3.86% glucose solution.
Continuous use of icodextrin solution in peritoneal
dialysis patients improves the control of fluid balance,
decreases blood pressure and the use of anti-
hypertensive medications, improves lipid profile, and
extends patients’ technical survival [74–77]. Icodextrin
solution is especially effective during peritonitis and
in high transporters in whom ultrafiltration is
significantly reduced with glucose solution due to
increased absorption of glucose from the peritoneal
cavity [39,78–80].
In summary, after several decades of experience
with peritoneal dialysis therapy, we have a much better
understanding of the functional properties of the
peritoneal membrane and the causes of its changes
during long-term dialysis. Several new, more
biocompatible solutions are now available in the clinic
and the outcome of peritoneal dialysis therapy is
expected to be further improved.
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